From Classical PKPD to Model-Informed Drug Development: Are “Digital Twins” a New Paradigm?
Academic source · Clinical Pharmacology & Therapeutics
Source published: · Event / reporting date: 2026-05-21
Site published: 2026-11-04 · Updated: 2026-11-04
This source is linked automatically. Choose a question to get started.
What the paper reports
This perspective examines digital-twin claims against established pharmacometric practice. It argues that individual simulation, sequential updating, and decision-focused uncertainty analysis have longstanding roots in PK/PD modeling. The author emphasizes that fundamental limits, including identifiability, remain relevant despite new terminology.
Why this paper is included
Useful for evaluating modeling claims without confusing a new label with demonstrated predictive performance.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections